RY
$90.90
+2.28
(+2.57%)
As of Oct 22, 2026, 9:30 PM EDT · cached
Price history
Today's analyst average
Analyst average over timeIndividual analyst targets
Analyst history starts Oct 12, 2026, the first target we tracked for RYTM.
Rhythm Pharmaceuticals Inc (RYTM) is trading up at $90.90 (+2.57%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
IPO: October 5, 2017 · $17.00 offering · NASDAQ · View IPO details →
Analyst price targets on RYTM
One firm's current price target on Rhythm Pharmaceuticals Inc: $130 — 43% above the current $90.9. Each is tracked to its date and scored the same way a member's call is.
- H.C. Wainwright $90.8 → $130 by Oct 2027 Oct 12, 2026 via Investing.com · H.C. Wainwright's track record
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
Rhythm Pharmaceuticals Inc revenue & net income history (FY2016–FY2025)
RevenueNet incomeNet margin (right axis, %)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $0 | $0 | $0 | $0 | $0 | $3.15M | $23.6M | $77.4M | $130.1M | $189.8M |
| Growth (year over year) | — | — | — | — | — | — | +649.5% | +227.6% | +68.1% | +45.8% |
| Gross profit | — | — | — | — | — | $2.56M | $21.5M | $68.1M | $116.8M | $170.3M |
| Gross margin | — | — | — | — | — | 81.0% | 91.0% | 88.0% | 89.7% | 89.7% |
| Operating income | −$25.9M | −$32.4M | −$78.4M | −$146.0M | −$136.6M | −$170.1M | −$179.2M | −$184.4M | −$265.5M | −$192.0M |
| Operating margin | — | — | — | — | — | −5391.9% | −757.9% | −238.1% | −204.0% | −101.2% |
| Net income | −$29.1M | −$33.7M | −$74.1M | −$140.7M | −$134.0M | −$69.6M | −$181.1M | −$184.7M | −$260.6M | −$196.5M |
| Net margin | — | — | — | — | — | −2207.1% | −766.2% | −238.5% | −200.3% | −103.6% |
| EPS (diluted) | −$2.85 | −$2.83 | −$2.39 | −$3.86 | −$3.04 | −$1.40 | −$3.47 | −$3.20 | −$4.34 | −$3.11 |
| Balance sheet | ||||||||||
| Cash and equivalents | $6.54M | $34.2M | $49.5M | $62.3M | $100.9M | $59.2M | $127.7M | $60.1M | $89.1M | $54.3M |
| Total assets | $12.3M | $151.7M | $260.2M | $308.5M | $187.1M | $329.5M | $382.5M | $332.7M | $392.3M | $480.2M |
| Total liabilities | $5.04M | $6.95M | $14.0M | $27.5M | $20.5M | $45.4M | $118.2M | $163.0M | $227.7M | $210.2M |
| Long-term debt | — | — | — | — | — | — | — | $106.1M | $108.3M | $100.9M |
| Shareholders' equity | −$32.7M | $144.8M | $246.3M | $281.0M | $166.5M | $284.2M | $264.3M | $169.8M | $21.7M | $139.1M |
| Cash flow | ||||||||||
| Operating cash flow | −$23.2M | −$29.5M | −$62.1M | −$122.8M | −$122.0M | −$146.0M | −$173.4M | −$136.2M | −$113.9M | −$115.7M |
| Capital expenditure | $1.06M | $133.0K | $722.0K | $3.38M | $214.0K | $434.0K | $281.0K | $47.0K | $0 | $953.0K |
| Free cash flow | −$24.3M | −$29.6M | −$62.8M | −$126.1M | −$122.2M | −$146.4M | −$173.7M | −$136.2M | −$113.9M | −$116.6M |
RevenueNet incomeNet margin (right axis, %)
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $33.3M | $41.8M | $32.7M | $48.5M | $51.3M | $57.3M | $60.1M | $71.3M |
| Growth (year over year) | +47.8% | +72.6% | +25.9% | +66.8% | +54.3% | +36.9% | +83.8% | +46.9% |
| Gross profit | $29.4M | $38.0M | $29.1M | $43.0M | $45.8M | $52.5M | $53.0M | $62.3M |
| Gross margin | 88.5% | 90.9% | 88.8% | 88.6% | 89.3% | 91.6% | 88.1% | 87.5% |
| Operating income | −$43.9M | −$41.3M | −$47.0M | −$45.3M | −$52.7M | −$47.1M | −$52.4M | −$48.6M |
| Operating margin | −132.0% | −98.6% | −143.7% | −93.4% | −102.6% | −82.2% | −87.1% | −68.1% |
| Net income | −$43.6M | −$43.3M | −$49.5M | −$46.6M | −$52.9M | −$47.5M | −$55.6M | −$49.3M |
| Net margin | −131.2% | −103.6% | −151.4% | −96.1% | −103.1% | −83.0% | −92.6% | −69.2% |
| EPS (diluted) | −$0.73 | −$0.71 | −$0.81 | −$0.75 | −$0.82 | −$0.73 | −$0.83 | −$0.73 |
| Balance sheet | ||||||||
| Cash and equivalents | $47.5M | $89.1M | $106.1M | $135.6M | $52.1M | $54.3M | $62.1M | $65.6M |
| Total assets | $363.6M | $392.3M | $386.7M | $372.7M | $506.9M | $480.2M | $442.3M | $437.3M |
| Total liabilities | $210.9M | $227.7M | $223.6M | $239.2M | $211.2M | $210.2M | $204.7M | $220.0M |
| Long-term debt | — | $108.3M | $107.9M | $106.0M | $103.4M | $100.9M | $98.3M | $93.4M |
| Shareholders' equity | $11.2M | $21.7M | $18.9M | −$11.9M | $148.8M | $139.1M | $122.9M | $103.0M |
| Cash flow | ||||||||
| Operating cash flow | −$25.2M | −$18.8M | −$40.4M | −$23.3M | −$26.6M | −$25.4M | −$44.2M | −$9.15M |
From Rhythm Pharmaceuticals Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Rhythm Pharmaceuticals Inc
- Headquarters
- Boston, Massachusetts From SEC filings, Oct 2026
Recent News (5)
-
Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026 BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with r…
-
Rhythm Pharmaceuticals launches IMCIVREE in Japan for obesity
Rhythm Pharmaceuticals launches IMCIVREE in Japan for obesity
-
Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity -- Launch follows MHLW approval of IMCIVREE for acquired hypothalamic obesity and inclusion on Japan's National Health Insurance drug price list -- -- IMCIVREE is the first approved therapy in Japan …
-
H.C. Wainwright raises Rhythm Pharmaceuticals stock price target to $130 on Japan approval
H.C. Wainwright raises Rhythm Pharmaceuticals stock price target to $130 on Japan approval
-
Rhythm (RYTM) Earnings Report: The Available Earnings Metric Delivers a Beat for the Current Session; Market Response: Shares Move 1.24% Up in the Latest Session - Earnings Expansion Phase Rhythm (RYTM) Earnings Report: The Available Earnings Metric Delivers a Beat for the Current Session; Market Response: Shares Move 1.24% Up in the Latest Session - Earnings Expansion Phase dars.gov.e…
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International